var data={"title":"Venlafaxine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Venlafaxine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7147?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=venlafaxine-drug-information\" class=\"drug drug_general\">see &quot;Venlafaxine: Drug information&quot;</a> and <a href=\"topic.htm?path=venlafaxine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Venlafaxine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5710003\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Suicidality and antidepressant drugs:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of venlafaxine or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Venlafaxine is not approved for use in pediatric patients.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233762\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Effexor XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233763\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Effexor XR;</li>\n      <li>Venlafaxine XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055989\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidepressant, Serotonin/Norepinephrine Reuptake Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055981\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=venlafaxine-drug-information\" class=\"drug drug_general\">see &quot;Venlafaxine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Attention-deficit/hyperactivity disorder (ADHD):</b> Limited data available: Children and Adolescents 8  to &lt;17 years: Oral: Immediate release:  Initial: 12.5 mg then titrate: Children &lt;40 kg: Increase by 12.5 mg/week to maximum daily dose: 50 mg/day in 2 divided doses or Children &ge;40 kg: Increase by 25 mg/week to maximum daily dose: 75 mg/day in 3 divided doses. Dosing based on an open-label clinical 5-week trial of 16 children and adolescents (mean age: 11.6 &plusmn; 2.3 years); mean dose: 60 mg/day (1.4 mg/kg/day) in 2 to 3 divided doses; ten patients completed the study [2 were lost to follow-up; 5 discontinued therapy due to adverse effects (4 had an increase in hyperactivity; 1 had severe nausea)]; venlafaxine decreased behavioral symptoms (but not cognitive symptoms) in 7 of 16 subjects (44%) (Olvera 1996). An initial dose of 37.5 mg given 3 times/day was used in an 11-year-old female with ADHD; the dose was slowly titrated to 100 mg given 3 times/day; after 6 weeks the patient showed moderate to marked improvement in symptoms, but developed hypertension; the dose was then decreased to 75 mg given 3 times/day with normalization of blood pressure (Pleak 1995).  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Autism spectrum disorders:</b> Limited data available: Children &ge; 3 years and Adolescents: Oral: Immediate release: One retrospective report is available; 10 patients (3 to 21 years of age; mean 10.5 &plusmn; 5.6 years) with autism spectrum disorders (autism, Asperger's syndrome, and pervasive developmental disorders not otherwise specified) received initial doses of 12.5 mg/day administered once daily at breakfast; doses were gradually titrated based on clinical response and side effects; mean final dose: 24.4 mg/day; range: 6.25 to 50 mg/day; 6 of the 10 patients were sustained-treatment responders (Hollander 2000). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Depression:</b> Limited data available: Children &ge;7 years and Adolescents &le;17 years: <b>Note:</b> Due to the lack of demonstrated efficacy and concerns about an increased risk for suicidal behavior, venlafaxine should be reserved for pediatric patients with major depression who do not respond to fluoxetine or sertraline (Dopheide 2006). Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Immediate release: One double-blind, placebo-controlled, 6-week study is available; 33 children and adolescents (8 to 17 years of age) with major depression completed the trial (16 received venlafaxine; for children 8 to 12 years, doses were initiated at 12.5 mg once daily for 3 days, then increased to 12.5 mg twice daily for 3 days, then increased to 12.5 mg given 3 times/day for the rest of the study; for adolescents 13 to 17 years, doses were initiated at 25 mg once daily for 3 days, then increased to 25 mg twice daily for 3 days, then increased to 25 mg given 3 times/day for the rest of the study; both venlafaxine and placebo patients improved over time; however, no significant difference in symptoms was noted between groups (ie, venlafaxine did not have a significant effect on symptoms or specific behaviors); the authors suggest this lack of efficacy may be due to the low doses used and short duration of treatment (Mandoki 1997). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Extended release: A large multicenter double-blind, placebo-controlled study of venlafaxine-ER in children and adolescents 7 to 17 years of age with major depression is ongoing; this study is using higher doses; initial: 37.5 mg/day for 1 week; with increases to 75 mg/day for weeks 2 to 8; results are not yet available (Weller 2000). One report of two 16-year-old patients used higher doses of venlafaxine (final doses: 112.5 mg/day and 150 mg/day) in combination with lithium to successfully treat major depression (Walter 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Discontinuation of therapy:</b> Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of reemerging symptoms. Evidence supporting ideal taper rates is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. In addition for long-term treated patients, WFSBP guidelines recommend tapering over 4 to 6 months. If intolerable withdrawal symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (APA 2010; Bauer 2002; Haddad 2001; NCCMH 2010; Schatzberg 2006; Shelton 2001; Warner 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">In clinical studies with extended-release venlafaxine, tapering was achieved by reducing the daily dose by 75 mg at 1-week intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>MAO inhibitor recommendations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Switching to or from an MAO inhibitor intended to treat psychiatric disorders:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of venlafaxine.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Allow 7 days to elapse between discontinuing venlafaxine and initiation of an MAO inhibitor intended to treat psychiatric disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Use with other MAO inhibitors (linezolid or IV methylene blue):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Do not initiate venlafaxine in patients receiving linezolid or IV methylene blue; consider other interventions for psychiatric condition.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving venlafaxine and potential benefits outweigh potential risks, discontinue venlafaxine promptly and administer linezolid or IV methylene blue. Monitor for serotonin  syndrome for 7 days or until 24 hours after the last dose of linezolid or IV methylene blue, whichever comes first. May resume venlafaxine 24 hours after the last dose of linezolid or IV methylene blue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Depression:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Immediate release tablets: Initial: 37.5 to 75 mg/day, administered in 2 or 3 divided doses; may increase in &le;75 mg/day increments at intervals of &ge;4 days as tolerated; usual dosage: 75 to 225 mg/day (maximum dose: 375 mg/day) (APA 2010)  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Extended release capsules or tablets: Initial: 37.5 to 75 mg once daily; in patients who are initiated at 37.5 mg once daily, may increase to 75 mg once daily after 4 to 7 days; dose may then be increased by &le;75 mg/day increments at intervals of &ge;4 days as tolerated; usual dosage: 75 to 225 mg once daily (maximum daily dose: 225 mg) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>Note:</b> Patients treated with a therapeutic dose with venlafaxine immediate release may be switched to venlafaxine extended release (ER) at the nearest equivalent dose (mg/day). Following the formulation switch individual dosage adjustments may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Generalized anxiety disorder:</b> Oral: Extended release capsules: Initial: 37.5 to 75 mg once daily; in patients who are initiated at 37.5 mg once daily, may increase to 75 mg once daily after 4 to 7 days; may then be increased by &le;75 mg/day increments at intervals of &ge;4 days as tolerated; usual dosage: 75 to 225 mg once daily (maximum daily dose: 225 mg) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Panic disorder:</b> Oral: Extended release capsules: Initial: 37.5 mg once daily for 1 week; may increase to 75 mg once daily after 7 days,  may then be increased by &le;75 mg/day increments at intervals of &ge;7 days; usual dosage: 75 to 225 mg once daily (maximum daily dose: 225 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> <b>Social anxiety disorder:</b> Oral: Extended release capsules or tablets: 75 mg once daily; no evidence that doses &gt;75 mg/day offer any additional benefit </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Discontinuation of therapy:</b> Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of reemerging symptoms. Evidence supporting ideal taper rates is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. In addition for long-term treated patients, WFSBP guidelines recommend tapering over 4 to 6 months. If intolerable withdrawal symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (APA 2010; Bauer 2002; Haddad 2001; NCCMH 2010; Schatzberg 2006; Shelton 2001; Warner 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">In clinical studies with extended-release venlafaxine, tapering was achieved by reducing the daily dose by 75 mg at 1-week intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>MAO inhibitor recommendations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Switching to or from an MAO inhibitor intended to treat psychiatric disorders:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of venlafaxine.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Allow 7 days to elapse between discontinuing venlafaxine and initiation of an MAO inhibitor intended to treat psychiatric disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Use with other MAO inhibitors (linezolid or IV methylene blue):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Do not initiate venlafaxine in patients receiving linezolid or IV methylene blue; consider other interventions for psychiatric condition.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">If urgent treatment with linezolid or IV methylene blue is required in a patient already receiving venlafaxine and potential benefits outweigh potential risks, discontinue venlafaxine promptly and administer linezolid or IV methylene blue. Monitor for serotonin syndrome for 7 days or until 24 hours after the last dose of linezolid or IV methylene blue, whichever comes first. May resume venlafaxine 24 hours after the last dose of linezolid or IV methylene blue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mild to moderate impairment (CrCl 30 to 89 mL/minute):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Immediate release: Reduce total daily dose by 25%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Extended release: Reduce total daily dose by 25% to 50%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe impairment: (CrCl &lt;30 mL/minute): Reduce total daily dose by 50% or more</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemodialysis: Reduce total daily dose by 50% or more</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mild to moderate impairment (Child-Pugh score 5 to 9): Reduce total daily dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe impairment (Child-Pugh score 10 to 15) or cirrhosis: Reduce total daily dose by 50% or more</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233734\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Effexor XR: 37.5 mg, 75 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 37.5 mg, 75 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 37.5 mg, 75 mg, 150 mg, 225 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233719\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874929\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Effexor XR: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020699s107lbl.pdf#page=36&amp;token=iqRdRgPwJzyJywRAJexi0S64BCBUn5KfrAtP9oGvRjYgQ4GmEGXAkenqOC3FMjk/eXhSJFhmFUeHt6RXivHreDxwDRvLsyaguI8bmsXno+nbznq/gGvbLzZcwJu/wbHc&amp;TOPIC_ID=12878\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020699s107lbl.pdf#page=36</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Venlafaxine extended release tablet:  <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022104s015lbl.pdf#page=35&amp;token=MXTHlzu2f6jTWWasC0z83IRrWAim8HRCHbjchVEWMpOG8HBWythDwwmWDeIDWKv41g4GDfO8ymo83YLJ0PIsUIkloqXcgXMz3I9V0Q0xnI1CuxenpSyBFXI0aF08dFYM&amp;TOPIC_ID=12878\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022104s015lbl.pdf#page=35</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Antidepressant medications: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ucm100211.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+tzXKjYwuZYZylkP+kRnn+doVL8tsWmc2MIZh/g1QzjAAGI4EzKpddG0l/j8K0NuhbXvXOgWPXisGp8KlvcP9h&amp;TOPIC_ID=12878\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ucm100211.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055993\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immediate release tablet: Administer with food </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Extended release capsule: Administer with food once daily at about the same time each day; swallow whole with fluid; do not crush, chew, divide, or place in water; capsule may be opened and entire contents sprinkled on spoonful of applesauce; swallow drug/food mixture immediately. Do not store for future use; do not chew contents (ie, pellets) of capsule; follow drug/food mixture with water to ensure complete swallowing of pellets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6075544\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate-release tablets and extended-release capsules: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended-release tablets: Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect from moisture and humidity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055992\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder (social phobia), and panic disorder (all indications: FDA approved in adults); has also been used to treat ADHD and autism in children and obsessive-compulsive disorder and chronic fatigue syndrome in adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914389\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Effexor may be confused with Effexor XR</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Effexor XR may be confused with Enablex</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Venlafaxine may be confused with Venclexta, venetoclax</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric patients: High-risk medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Serotonin/Norepinephrine Reuptake Inhibitors (SNRIs) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to its potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233808\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypertension, hypotension, increased blood pressure, increased pulse, orthostatic hypotension, syncope, tachycardia, vasodilation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams, agitation, akathisia, anorgasmia, apathy, chills, confusion, depersonalization, dizziness, drowsiness, hallucination, hypertonia, insomnia, manic reaction, myoclonus, nervousness, paresthesia, seizure, suicidal ideation, yawning</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, diaphoresis, ecchymoses, pruritus, skin photosensitivity, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased libido, hypercholesterolemia, hypermenorrhea, increased serum triglycerides, orgasm abnormal (men), weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, bruxism, constipation, diarrhea, dysgeusia, gastrointestinal hemorrhage, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Abnormal uterine bleeding, ejaculatory disorder, impotence, urinary frequency, urinary incontinence, urinary retention, urination disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hematoma, petechia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Accommodation disturbance, mydriasis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Epistaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal hepatic function tests, agranulocytosis, anaphylaxis, angioedema, angle-closure glaucoma, aplastic anemia, ataxia, delirium, dyspnea, eosinophilic pneumonitis, erythema multiforme, extrapyramidal reaction (including dystonia, dyskinesia), hepatitis, hypomania, hyponatremia, increased intraocular pressure (open-angle glaucoma) (Botha 2016), increased serum prolactin, interstitial pulmonary disease, mucous membrane bleeding, neuroleptic malignant syndrome, neutropenia, pancreatitis, pancytopenia, prolonged bleeding time, prolonged Q-T Interval on ECG, rhabdomyolysis, serotonin syndrome, SIADH, Stevens-Johnson syndrome, tardive dyskinesia, thrombocytopenia, toxic epidermal necrolysis, ventricular fibrillation, ventricular tachycardia (including torsades de pointes), withdrawal syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233742\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to venlafaxine or any component of the formulation; use of MAOIs intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing the MAOI); initiation of MAOI intended to treat psychiatric disorders within 7 days of discontinuing venlafaxine; initiation in patients receiving linezolid or IV methylene blue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233723\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Major psychiatric warnings:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal thinking/behavior: <b>[US Boxed Warning]: Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (18 to 24 years of age) in short-term studies of major depressive disorder (MDD) and other psychiatric disorders; consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients of all ages for clinical worsening, suicidality, or unusual changes in behavior, particularly during the first few months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider.</b> A medication guide concerning the use of antidepressants in children and teenagers should be dispensed with each prescription. <b>Venlafaxine is not approved for use in pediatric patients.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their health care provider if any of these symptoms or worsening depression or psychosis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anxiety/insomnia: May cause increase in anxiety, nervousness, and insomnia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding risk: May impair platelet aggregation resulting in increased risk of bleeding events, particularly if used concomitantly with aspirin, NSAIDs, warfarin, or other anticoagulants. Bleeding related to SSRI or SNRI use has been reported to range from relatively minor bruising and epistaxis to life-threatening hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyslipidemia: May cause significant increases in serum total cholesterol and triglycerides; monitor during long-term treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures: Bone fractures have been associated with antidepressant treatment. Consider the possibility of a fragility fracture if an antidepressant-treated patient presents with unexplained bone pain, point tenderness, swelling, or bruising (Rabenda, 2013; Rizzoli, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Dose-related increases in systolic and diastolic blood pressure have been documented. Monitor blood pressure regularly, and if sustained increases noted, consider dose reduction or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: May cause mild pupillary dilation which in susceptible individuals can lead to an episode of narrow-angle glaucoma. Consider evaluating patients who have not had an iridectomy for narrow-angle glaucoma risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary events: Interstitial lung disease and eosinophilic pneumonia have been rarely reported. May present as progressive dyspnea, cough, and/or chest pain. Prompt evaluation and possible discontinuation of therapy may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MAO inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sexual dysfunction: May cause or exacerbate sexual dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; SIADH and hyponatremia: SSRIs and SNRIs have been associated with the development of SIADH; hyponatremia has been reported rarely (including severe cases with serum sodium &lt;110 mmol/L). Age (the elderly), volume depletion, and/or concurrent use of diuretics likely increases risk. Discontinue treatment in patients with symptomatic hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight loss and anorectic effects: Dose-dependent weight loss has been observed in both pediatric and adult patients; weight loss was not limited to those experiencing reduced appetite.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: May cause sustained increase in blood pressure or tachycardia. Control pre-existing hypertension prior to initiation of venlafaxine. Use caution in patients with recent history of MI, unstable heart disease, cerebrovascular conditions, or hyperthyroidism. Hypertensive effect is dose related and increases are generally modest (12 to 15 mm Hg diastolic).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution; clearance is decreased and plasma concentrations are increased; dosage reduction recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mania/hypomania: May precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder, including details regarding family history of suicide, bipolar disorder, and depression. <b>Venlafaxine is not FDA approved for the treatment of bipolar depression.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution; clearance is decreased and plasma concentrations are increased; dosage reduction recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use caution in patients with a previous seizure disorder; discontinue in any patient who develops seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may have a higher risk of SIADH or hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Small differences in height and weight have been observed in pediatric patients receiving venlafaxine, particularly those &lt;12 years of age, compared to placebo.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation syndrome: Abrupt discontinuation or interruption of antidepressant therapy has been associated with a discontinuation syndrome.  Symptoms arising may vary with antidepressant however commonly include nausea, vomiting, diarrhea, headaches, lightheadedness, dizziness, diminished appetite, sweating, chills, tremors, paresthesias, fatigue, somnolence, and sleep disturbances (eg, vivid dreams, insomnia).  Less common symptoms include electric shock-like sensations, cardiac arrhythmias (more common with tricyclic antidepressants), myalgias, parkinsonism, arthralgias, and balance difficulties. Psychological symptoms may also emerge such as agitation, anxiety, akathisia, panic attacks, irritability, aggressiveness, worsening of mood, dysphoria, mood lability, hyperactivity, mania/hypomania, depersonalization, decreased concentration, slowed thinking, confusion, and memory or concentration difficulties. Greater risks for developing a discontinuation syndrome have been associated with antidepressants with shorter half-lives, longer durations of treatment, and abrupt discontinuation.  For antidepressants of short or intermediate half-lives, symptoms may emerge within 2 to 5 days after treatment discontinuation and last 7 to 14 days (APA 2010; Fava 2006; Haddad 2001; Shelton 2001; Warner 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819289\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May cause anxiety, nervousness, and insomnia; in children treated for ADHD, an increase in hyperactivity (behavioral activation) was reported (Olvera 1996). May cause anorexia and significant, dose related weight loss; use with caution in patients where weight loss is undesirable; may adversely affect weight and height in children; monitor closely in pediatric patients; weight loss in pediatric patients was not limited to those with venlafaxine-associated anorexia; reduction in growth rate, as assessed by height, was greater in children &lt;12 years of age than in adolescents. A case of priapism has been reported in an adolescent patient (Samuel 2000). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233795\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233728\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12878&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Specifically, risks of psychomotor impairment may be enhanced. Alcohol (Ethyl) may enhance the hepatotoxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Particularly duloxetine and milnacipran. Management: Patients receiving serotonin/norepinephrine reuptake inhibitors (SNRIs) should be advised to avoid alcohol.  Monitor for increased psychomotor impairment and hepatotoxicity in patients who consume alcohol during treatment with SNRIs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the antihypertensive effect of Alpha2-Agonists. <b> Exceptions: </b>Apraclonidine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Venlafaxine may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Serotonin/Norepinephrine Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: Serotonin/Norepinephrine Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with serotonin/norepinephrine reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.  While methylene blue and linezolid are expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<b> Exceptions: </b>Linezolid; Methylene Blue; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Serotonin/Norepinephrine Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Venlafaxine. Management: Monitor for increased venlafaxine levels/adverse effects (e.g., hallucinations, agitation, confusion) with propafenone initiation/dose increase. Conversely, monitor for decreased venlafaxine levels with profapenone discontinuation/dose decrease.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraZODone: Venlafaxine may enhance the serotonergic effect of TraZODone. This could result in serotonin syndrome. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Venlafaxine may enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May enhance the adverse/toxic effect of Venlafaxine. Voriconazole may increase the serum concentration of Venlafaxine.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233729\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233745\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Venlafaxine and its active metabolite ODV cross the human placenta. An increased risk of teratogenic effects following venlafaxine exposure during pregnancy has not been observed, based on available data. The risk of spontaneous abortion may be increased. Neonatal seizures and neonatal abstinence syndrome have been noted in case reports following maternal use of venlafaxine during pregnancy. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hyper- or hypotonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SNRI or a discontinuation syndrome and may be consistent with serotonin syndrome associated with treatment. The long-term effects of in utero SNRI/SSRI exposure on infant development and behavior are not known.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of venlafaxine may be altered. Women should be monitored for decreased efficacy. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants (NPRAD). Women 18 to 45 years of age or their health care providers may contact the registry by calling 844-405-6185. Enrollment should be done as early in pregnancy as possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055988\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor blood pressure regularly, especially in patients with high baseline blood pressure; monitor renal and hepatic function (for possible dose reductions), heart rate, weight, height, serum cholesterol and sodium. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233722\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake. Venlafaxine and ODV have no significant activity for muscarinic cholinergic, H<sub>1</sub>-histaminergic, or alpha<sub>2</sub>-adrenergic receptors. Venlafaxine and ODV do not possess MAO-inhibitory activity. Venlafaxine functions like an SSRI in low doses (37.5 mg/day) and as a dual mechanism agent affecting serotonin and norepinephrine at doses above 225 mg/day (Harvey 2000; Kelsey 1996).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233741\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: &ge;92%; extended-release has a slightly slower rate of absorption compared to immediate-release</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: Venlafaxine 7.5 &plusmn; 3.7 L/kg, ODV 5.7 &plusmn; 1.8 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Venlafaxine 27% &plusmn; 2%, ODV 30% &plusmn; 12%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP2D6 to active metabolite, O-desmethylvenlafaxine (ODV); other metabolites include N-desmethylvenlafaxine and N,O-didesmethylvenlafaxine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: ~45%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Venlafaxine: 5 &plusmn; 2 hours (immediate-release), 10.7 &plusmn; 3.2 hours (extended-release); ODV: 11 &plusmn; 2 hours (immediate-release), 12.5 &plusmn; 3 hours (extended-release); prolonged with cirrhosis (venlafaxine: ~30%, ODV: ~60%), renal impairment (venlafaxine: ~50%, ODV: ~40%), and during dialysis (venlafaxine: ~180%, ODV: ~142%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Venlafaxine: 2 hours, ODV: 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Venlafaxine: 6.3 &plusmn; 2.3 hours, ODV: 11.6 &plusmn; 2.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~87%; 5% of total dose as unchanged drug; 29% of total dose as unconjugated ODV; 26% of total dose as conjugated ODV; 27% of total dose as minor inactive metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults with cirrhosis: Venlafaxine: Clearance is decreased by ~50%; ODV: Clearance is decreased by ~30%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults with more severe cirrhosis: Venlafaxine: Clearance is decreased by ~90%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults with renal impairment (GFR: 10-70 mL/minute): Venlafaxine: Clearance is decreased by ~24%; ODV: Clearance unchanged versus normal subjects</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults on dialysis: Venlafaxine: Clearance decreased by ~57%; ODV: Clearance decreased by ~56%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233744\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Effexor XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5 mg (30): $452.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (30): $506.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $551.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Venlafaxine HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5 mg (30): $124.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (30): $139.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $152.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Venlafaxine HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5 mg (30): $185.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (30): $207.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $226.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">225 mg (30): $476.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Venlafaxine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $194.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">37.5 mg (100): $200.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $206.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $218.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $231.53</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233748\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Altven (AU);</li>\n      <li>Alventa (HR, RO, UA);</li>\n      <li>Ansifix SR (EC);</li>\n      <li>Avenfax XR (SG);</li>\n      <li>Blossom (CN);</li>\n      <li>Calmdown (TW);</li>\n      <li>Cofexor XL ER (KR);</li>\n      <li>Deprevix (HK);</li>\n      <li>Dobupal (ES);</li>\n      <li>Easyfor SR (TW);</li>\n      <li>Efectin (AT, CZ, HU);</li>\n      <li>Efectin EP (RO);</li>\n      <li>Efectin ER (BG);</li>\n      <li>Efexiva (HR, SI);</li>\n      <li>Efexor (AE, AR, BE, BH, BR, CH, CO, DK, EE, EG, FI, GB, GR, IE, IT, JO, LU, NL, PE, PK, QA, SA, SE, TR, ZA);</li>\n      <li>Efexor Depot (FI, IS, NO, SE);</li>\n      <li>Efexor ER (CH);</li>\n      <li>Efexor XL (ID, MT);</li>\n      <li>Efexor XR (AE, AR, AU, BH, BR, CL, CN, CO, CY, EC, EE, HK, IL, KR, KW, LB, LT, MX, MY, NZ, PE, PH, PT, QA, SA, SG, TH, VE, VN);</li>\n      <li>Effexor (FR);</li>\n      <li>Effexor SR (JP);</li>\n      <li>Effexor XR (BB);</li>\n      <li>Elafax (PY, UY);</li>\n      <li>Elafax XR (PY, UY);</li>\n      <li>Enlafax-XR (AU);</li>\n      <li>Evaxiner (CR, DO);</li>\n      <li>Evaxiner XR (GT, HN, NI, PA, SV);</li>\n      <li>Faxine (TW);</li>\n      <li>Ireven (IE);</li>\n      <li>Lafax (BD);</li>\n      <li>Lanvexin (LV);</li>\n      <li>Levensa SR (KR);</li>\n      <li>Neurofax SR (LK);</li>\n      <li>Nevola (BD);</li>\n      <li>Rafax XR (TW);</li>\n      <li>Rudomel XL (GB);</li>\n      <li>Sesaren XR (CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Trevilor (DE);</li>\n      <li>Trewilor (AT);</li>\n      <li>Valosine (TW);</li>\n      <li>Valosine SR (TH);</li>\n      <li>Vandral Retard (ES);</li>\n      <li>Vaxor (JO);</li>\n      <li>Vedixal (IE);</li>\n      <li>Velaksyn (UA);</li>\n      <li>Velapax (RU);</li>\n      <li>Velaxin (HK);</li>\n      <li>Venax (BD);</li>\n      <li>Venaxine (QA);</li>\n      <li>Venex (IE);</li>\n      <li>Venexor (HK, JO);</li>\n      <li>Venexor XR (TZ);</li>\n      <li>Venexor XR SR (KR);</li>\n      <li>Veniz XR (LK);</li>\n      <li>Veniz-XR (IN);</li>\n      <li>Venla (IL);</li>\n      <li>Venla RBX (AU);</li>\n      <li>VenlaBlue XL (GB);</li>\n      <li>Venlafact SR (KR);</li>\n      <li>Venlalic XL (GB);</li>\n      <li>Venlax (BD, CL, LK);</li>\n      <li>Venlax Retard (CL);</li>\n      <li>Venlax XR (LB);</li>\n      <li>Venlaxor (LV);</li>\n      <li>Venlift (UA);</li>\n      <li>Venlift OD 75 (TZ);</li>\n      <li>Venlor XR (HK);</li>\n      <li>Vensir (IE);</li>\n      <li>Vensir XL (GB);</li>\n      <li>Ventaxin OR (KR);</li>\n      <li>Venxor (HK);</li>\n      <li>Viepax (IL);</li>\n      <li>Viepax XR (IL, SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Psychiatric Association (APA). Treatment recommendations for patients with major depressive disorder. 3rd ed. May 2010. Available at http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/23879318/pubmed\" target=\"_blank\" id=\"23879318\">23879318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/12479080/pubmed\" target=\"_blank\" id=\"12479080\">12479080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berle JO, Spigset O. Antidepressant use during breastfeeding. <i>Curr Womens Health Rev</i>. 2011;7(1):28-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/22299006/pubmed\" target=\"_blank\" id=\"22299006\">22299006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopheide JA, &quot;Recognizing and Treating Depression in Children and Adolescents,&quot; <i>Am J Health Syst Pharm</i>, 2006, 63(3):233-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/16434782/pubmed\" target=\"_blank\" id=\"16434782\">16434782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Emslie GJ, Yeung PP, and Kunz NR, &quot;Long-Term, Open-Label Venlafaxine Extended-Release Treatment in Children and Adolescents With Major Depressive Disorder,&quot; <i>CNS Spectr</i>, 2007, 12(3):223-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/17329983/pubmed\" target=\"_blank\" id=\"17329983\">17329983</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):14-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/16683858/pubmed\" target=\"_blank\" id=\"16683858\">16683858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/11347722/pubmed\" target=\"_blank\" id=\"11347722\">11347722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollander E, Kaplan A, Cartwright C, et al, &ldquo;Venlafaxine in Children, Adolescents, and Young Adults With Autism Spectrum Disorders: An Open Retrospective Clinical Report,&rdquo; <i>J Child Neurol</i>, 2000, 15(2):132-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/10695900 /pubmed\" target=\"_blank\" id=\"10695900 \">10695900 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ilett KF, Hackett LP, Dusci LJ, et al, &ldquo;Distribution and Excretion of Venlafaxine and O-Desmethylvenlafaxine in Human Milk,&rdquo; <i>Br J Clin Pharmacol</i>, 1998, 45(5):459-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/9643618 /pubmed\" target=\"_blank\" id=\"9643618 \">9643618 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lessard E, Yessine MA, Hamelin BA, et al, &ldquo;Diphenhydramine Alters the Disposition of Venlafaxine Through Inhibition of CYP2D6 Activity in Humans,&rdquo; <i>J Clin Psychopharmacol</i>, 2001, 21(2):175-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/11270914/pubmed\" target=\"_blank\" id=\"11270914\">11270914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levinson-Castiel R, Merlob P, Linder N, et al, &quot;Neonatal Abstinence Syndrome After <i>in utero</i> Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants,&quot; <i>Arch Pediatr Adolesc Med</i>, 2006, 160(2):173-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/16461873/pubmed\" target=\"_blank\" id=\"16461873\">16461873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandoki MW, Tapia MR, Tapia MA, et al, &ldquo;Venlafaxine in the Treatment of Children and Adolescents With Major Depression,&rdquo; <i>Psychopharmacol Bull</i>, 1997, 33(1):149-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/9133767/pubmed\" target=\"_blank\" id=\"9133767\">9133767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/22132433/pubmed\" target=\"_blank\" id=\"22132433\">22132433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newport DJ, Ritchie JC, Knight BT, et al, &quot;Venlafaxine in Human Breast Milk and Nursing Infant Plasma: Determination of Exposure,&quot; <i>J Clin Psychiatry</i>, 2009, 70(9):1304-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/19607765/pubmed\" target=\"_blank\" id=\"19607765\">19607765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olvera RL, Pliszka SR, Luh J, et al, &ldquo;An Open Trial of Venlafaxine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,&rdquo; <i>J Child Adolesc Psychopharmacol</i>, 1996, 6(4):241-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/9231317 /pubmed\" target=\"_blank\" id=\"9231317 \">9231317 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pleak RR and Gormly LJ, &ldquo;Effects of Venlafaxine Treatment for ADHD in a Child,&rdquo; <i>Am J Psychiatry</i>, 1995, 152(7):1099.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/7793453/pubmed\" target=\"_blank\" id=\"7793453\">7793453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabenda V, Nicolet D, Beaudart C, Bruy&egrave;re O, Reginster JY. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/22638709/pubmed\" target=\"_blank\" id=\"22638709\">22638709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/22659406/pubmed\" target=\"_blank\" id=\"22659406\">22659406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/23979084/pubmed\" target=\"_blank\" id=\"23979084\">23979084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samuel RZ, &ldquo;Priapism Associated With Venlafaxine Use,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 2000, 39(1):16-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/10638063/pubmed\" target=\"_blank\" id=\"10638063\">10638063</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/16683860/pubmed\" target=\"_blank\" id=\"16683860\">16683860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/15014601/pubmed\" target=\"_blank\" id=\"15014601\">15014601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/26204124/pubmed\" target=\"_blank\" id=\"26204124\">26204124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walter G, Lyndon B, and Kubb R, &ldquo;Lithium Augmentation of Venlafaxine in Adolescent Major Depression,&rdquo; <i>Aust N Z J Psychiatry</i> 1998, 32(3):457-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/9672738/pubmed\" target=\"_blank\" id=\"9672738\">9672738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74(3):449-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/16913164/pubmed\" target=\"_blank\" id=\"16913164\">16913164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weller EB, Weller RA, and Davis GP, &ldquo;Use of Venlafaxine in Children and Adolescents: A Review of Current Literature,&rdquo; <i>Depress Anxiety</i>, 2000, 12(Suppl 1):85-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venlafaxine-pediatric-drug-information/abstract-text/11098420/pubmed\" target=\"_blank\" id=\"11098420\">11098420</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12878 Version 255.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5710003\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F233762\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F233763\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1055989\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1055981\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F233734\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F233719\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874929\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1055993\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F6075544\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1055992\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7914389\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F233808\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F233742\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F233723\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819289\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F233795\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F233728\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F233729\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F233745\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1055988\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F233722\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F233741\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F233744\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F233748\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12878|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=venlafaxine-drug-information\" class=\"drug drug_general\">Venlafaxine: Drug information</a></li><li><a href=\"topic.htm?path=venlafaxine-patient-drug-information\" class=\"drug drug_patient\">Venlafaxine: Patient drug information</a></li></ul></div></div>","javascript":null}